INTRAVESICAL INSTILLATION of cytotoxic chemotherapy or immunotherapy is used to treat existing tumors, reduce or postpone tumor recurrence, and delay or prevent tumor progression and subsequent ...

Intravesical therapy involving bacillus Calmette–Guérin (BCG) is standard of care for high-grade, noninvasive urothelial carcinoma, with reported cure rates higher than 70%. Systemic infection occurs ...

First Bladder Cancer Patient Dosed with Commercially Available Intravesical Gene Therapy ADSTILADRIN® (nadofaragene firadenovec-vncg) Urologists treating eligible high-risk bladder cancer patients at ...

Phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of BCG-refractory non-muscle-invasive bladder cancer. A gene expression signature associated with sensitivity to ...

Potential to transform care and access to treatment for this growing patient population PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic ...

PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty ...

In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...

PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty cancers, ...